For more than 30 years, MUSC Hollings Cancer Center has been South Carolina's leader in blood and bone marrow transplantation and CAR-T cell therapy. We are the only Foundation for Accreditation of Cellular Therapy (FACT)-accredited combined adult and pediatric Blood and Marrow Transplant (BMT) and Immune Effector Cellular Therapy (IEC) program in the state.
Our experience and innovation with adult and pediatric blood and bone marrow transplantation and CAR-T cell therapy have resulted in outcomes that are among the best in the country. Our internationally recognized team of specialists and researchers have reduced associated complications, making transplantation possible for people not previously eligible.
As a pioneer in blood and bone marrow transplant and CAR-T research, we are the definitive source of hope for many adult and pediatric patients battling acute and chronic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and other diseases. We perform transplants for a variety of non-malignant conditions as well, including bone marrow failure syndromes, sickle cell disease, and immunodeficiencies.
By making greater efforts to provide access and break down barriers, we are successfully transplanting patients who have fewer available matches and therefore may be overlooked by other transplant centers.
We have the expertise and the caring team to get you through treatment. Our inpatient pediatric and adult units regularly rank in the top 1-3% in the nation in Press Ganey's patient satisfaction surveys.
Other distinctions include:
A designated blood and bone marrow transplant center for South Carolina's Medicaid program.
South Carolina's only approved umbilical cord blood transplant program.
South Carolina's only pediatric blood and bone marrow transplant program.
A National Marrow Donor Program collection and transplant center since 1993.
Accredited by FACT (Foundation for the Accreditation of Cellular Therapy) since 2003.
At Hollings, our Blood and Marrow Transplant team creates an individualized treatment plan that is unique to each patient's needs and provides curative therapy for a broad range of illnesses. We also offer opportunities for patients to participate in clinical trials, including several for the prevention and treatment of graft-versus-host disease.
Delivering leading care
CAR-T cell therapy
CAR-T cell therapy (chimeric antigen receptor T-cell therapy) re-engineers your immune cells to prime them to target cancer cells. MUSC Hollings Cancer Center has offered this therapy since 2019. We are also the only center in South Carolina with a pediatric CAR-T cell therapy program.
Our BMT program was one of 12 – out of 172 across the U.S. performing allogeneic transplants – that performed above expectations, according to the 2024 CIBMTR/NMDP report, which averaged the years 2020-2022.
